ClinicalTrials.gg
CompletedNCT02438306Updated Sep 19, 2025

CardiAMP™ Cell Therapy for Heart Failure Trial

A Phase 3 interventional study of Autologous cell therapy and Sham in Heart Failure, Systolic, sponsored by BioCardia, Inc.. Completed at 24 sites in 2 countries. Open to participants aged 21 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-09-19.

Sponsored by BioCardia, Inc. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
21 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Heart Failure, Systolic with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Heart Failure, Systolic · United States.

Enrollment
20th of 69
125 · median 40
Started
2016
with 8 others
Phase 3
Only one
of the 83
Registered
17th of 83
by date
Lead sponsor
2 of 83
BioCardia, Inc.

Among the 83 studies in Heart Failure, Systolic with a site in United States, this one is the 20th largest by enrollment of the 69 interventional ones that give a count, is one of 9 that started in 2016, is the only one in phase 3, and was the 17th registered.

Heart Failure, Systolic

230 studies on the registry are indexed under Heart Failure, Systolic; 50 are open to participants now.

Browse Heart Failure, Systolic studies →

Open to participants now

16 of the 83 studies in Heart Failure, Systolic with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 28 Heart Failure, Systolic studies recruiting now, 18 (64%) set no upper age limit and 2 (7%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 21 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Heart Failure, Systolic with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, multi-center, randomized, controlled, patient- and evaluator-blinded study comparing treatment with the CardiAMP cell therapy to a sham control treatment. A roll-in phase with a maximum of 10 subjects may occur.

Read the detailed description

Heart failure is a clinical condition in which the output of blood from the heart is insufficient to meet the metabolic demands of the body. In 2015, the American Heart Association, or AHA, report on heart disease statistics estimated that there are 5.7 million Americans over the age of 20 that have heart failure. Heart failure is increasingly prevalent due to the aging population and the increase in major cardiovascular risk factors, including obesity and diabetes.

The AHA also estimates that one in five adults will develop heart failure after the age of 40. During heart failure progression, the heart steadily loses its ability to respond to increased metabolic demand, and mild exercise soon exceeds the heart's ability to maintain adequate output. Towards the end stage of the disease, the heart cannot pump enough blood to meet the body's needs at rest. At this stage, fluids accumulate in the extremities or in the lungs making the patient bedridden and unable to perform the activities of daily living. The long-term prognosis associated with heart failure is approximately 50% mortality at five years following the initial diagnosis.

CardiAMP cell therapy is a comprehensive therapeutic treatment that comprises (i) a point of care cell processing platform and (ii) a biotherapeutic delivery system. CardiAMP cell therapy is the first comprehensive therapeutic treatment utilizing a patient's own cells for the treatment of ischemic heart failure with reduced ejection fraction. In the screening process, the physician extracts a small sample of the patient's bone marrow in an outpatient procedure performed under local anesthesia. The clinic sends the sample to a central diagnostic lab, which tests the sample. For the study treatment, a clinician collects and then prepares the patient's own bone marrow mononuclear cells, or autologous cells, using the CardiAMP point of care cell processing platform, which a cardiologist then delivers into the heart using the Helix biotherapeutic delivery system.

BioCardia intends to submit data obtained from this clinical trial in a Pre-Market Approval Application to the United States Food and Drug Administration

03

Conditions studied

  • Heart Failure, Systolic
04

Who can participate

Ages eligible
21 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (NYHA) Class II or III
  • A diagnosis of chronic ischemic left ventricular dysfunction secondary to myocardial infarction (MI) as defined by selected criteria.
  • On stable evidence-based medical and device therapy for ischemic etiology heart failure, per the ACC/AHA Heart Failure guidelines, for at least three (3) months prior to randomization.
  • between 20% and 40%.
  • Qualification of a pre-procedure screening of the patient's bone-marrow characteristics

Exclusion criteria

Exclusion Criteria:

  • Other cardiac or vascular system or other health-related criteria which may be seen in a patient's history and physical examination.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    CardiAMP cell therapy

    Placement of an introducer guidewire, performance of a left ventriculogram, and treatment with autologous cell therapy.

    Biological: Autologous cell therapy

  • Sham comparator
    Sham Comparator

    Placement of an introducer guidewire and performance of a left ventriculogram with no autologous cell therapy treatment.

    Other: Sham

Interventions

  • BiologicalAutologous cell therapy

    Autologous cell therapy delivered into the heart muscle using the CardiAMP Cell Therapy System. The CardiAMP Cell Therapy System consists of the CardiAMP Cell Separator, a cardiac delivery catheter, and flexible tip guide catheter.

  • OtherSham

    An introducer guidewire is placed into the heart and left ventriculography is performed just like it is in the Experimental Arm but no autologous cell therapy is delivered.

06

What researchers measure

Primary outcomes

  1. A composite endpoint based on a 3-tiered Finkelstein-Schoenfeld (FS) hierarchical analysis.

    The tiers include (1) all-cause death, (2) non-fatal MACCE events, and (3) change for 6MWD from baseline to month 12.

    Time frame: 12 Months

Secondary outcomes

  1. Minnesota Living with Heart Failure Questionnaire (MLHFQ)

    Mean change in quality of life score as measured by the MLHFQ at 12 months compared to baseline (superiority, treatment vs sham)

    Time frame: 12 months

  2. Survival

    Overall survival compared between both study arms (non-inferiority, treatment vs sham)

    Time frame: 12 Months

  3. Time to first Major Adverse Cardiac Events (MACE)

    Time to first MACE, defined as the composite of all-cause death, hospitalization for worsening heart failure, nonfatal recurrent myocardial infarction, placement of a left ventricular assist device (LVAD), or heart transplantation (non-inferiority, treatment vs sham)

    Time frame: 12 months

07

Study locations

24 sites
  • Mayo Clinic
    Phoenix, Arizona 85054, United States
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • Stanford Medical Center, Stanford Health Care
    Palo Alto, California 94305, United States
  • California Pacific Medical Center
    San Francisco, California 94115, United States
  • University of Colorado, Denver
    Aurora, Colorado 80045, United States
  • Morton Plant Mease Health Care
    Clearwater, Florida 33756, United States
  • University of Florida - College of Medicine/ div of Cardiovascular Medicine
    Gainesville, Florida 32606, United States
  • Iowa Heart
    Des Moines, Iowa 50266, United States
  • John Hopkins University School of Medicine - Dept of Cardiology
    Baltimore, Maryland 21287, United States
  • Suburban Hospital
    Bethesda, Maryland 20814, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Michigan Cardiovascular Institute
    Saginaw, Michigan 48601, United States
  • Michigan Heart - St.Joseph Mercy Health System (Trinity Health)
    Ypsilanti, Michigan 48197, United States
  • Atlantic Health System
    Morristown, New Jersey 07960, United States
  • New York University School of Medicine
    New York, New York 10010, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Oklahoma Heart
    Tulsa, Oklahoma 74104, United States
  • Stern Cardiovascular Foundation
    Memphis, Tennessee 38103, United States
  • Virginia Commonwealth University (VCU) Medical Center
    Richmond, Virginia 23298, United States
  • Division of Cardiovascular Medicine, University of Wisconsin Hospital and Clinics
    Madison, Wisconsin 53792-0001, United States
  • St. Paul's Hospital
    Vancouver, British Columbia, Canada
  • London Health Sciences Center
    London, Ontario, Canada
  • Ottawa Heart Institute
    Ottawa, Ontario KIY 4W7, Canada
  • Unity Health Toronto
    Toronto, Ontario, Canada
08

References and documents

Publications

  • Raval AN, Johnston PV, Duckers HJ, Cook TD, Traverse JH, Altman PA, Dhingra R, Hematti P, Borrello I, Anderson RD, Pepine CJ. Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasibility results from CardiAMP heart failure roll-in cohort. Int J Cardiol. 2021 Mar 1;326:131-138. doi: 10.1016/j.ijcard.2020.10.043. Epub 2020 Oct 20. PubMed 33091520 ↗
  • Raval AN, Cook TD, Duckers HJ, Johnston PV, Traverse JH, Abraham WT, Altman PA, Pepine CJ. The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: Trial rationale and study design. Am Heart J. 2018 Jul;201:141-148. doi: 10.1016/j.ahj.2018.03.016. Epub 2018 Apr 3. PubMed 29803986 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Feb 2025, 98 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2015
First posted
May 8, 2015
StartActual
Dec 2016
Primary completionActual
Feb 2025
CompletionActual
Jun 2025
Last update
Sep 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02438306
Lead sponsor
BioCardia, Inc.
Responsible party
Sponsor
First posted
May 8, 2015
Start date
Dec 2016
Primary completion
Feb 2025
Completion
Jun 2025
Last update
Sep 19, 2025

Study contacts

Carl Pepine, MD
principal investigator · University of Florida
Amish Raval, MD
principal investigator · University of Wisconsin, Madison
Duncan Stewart, MD
principal investigator · Ottawa Heart Institute Research Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion